This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Exelixis Appoints Executive Vice President And General Counsel

Exelixis, Inc. (NASDAQ: EXEL) today announced the appointment of Jeffrey J. Hessekiel, J.D., as executive vice president and general counsel. Mr. Hessekiel is a veteran legal professional with more than a decade of experience in the biopharmaceutical industry, as well as six years spent in general corporate and litigation practice in Silicon Valley. His legal expertise in pharmaceutical commercialization, compliance, and risk management will benefit Exelixis following its first product launch and in anticipation of top-line data from as many as four phase 3 pivotal trials later this year.

As Exelixis’ general counsel, Mr. Hessekiel is a key member of the company’s senior leadership team and is responsible for overseeing the global legal function. Mr. Hessekiel joins Exelixis from Arnold & Porter LLP, where as senior counsel he advised emerging growth and public companies, primarily in the life sciences sector, on complex legal issues connected with strategic transactions, healthcare compliance programs and investigations, and regulatory matters. Previously, from 2002 to 2012, he held key legal and compliance roles at Gilead Sciences, Inc., rising to the positions of vice president, commercial legal affairs and litigation, and then chief compliance and quality officer. Prior to joining Gilead, Mr. Hessekiel practiced corporate law at Wilson Sonsini Goodrich & Rosati, and at Heller Ehrman White & McAuliffe. He received his J.D. from George Washington University’s School of Law, and his B.A. from Duke University .

“Jeff’s appointment comes at an important time for Exelixis, as we strive to fully maximize the opportunity for cabozantinib and further develop cabozantinib into a major oncology product,” said Michael M. Morrissey, Ph.D., president and chief executive officer of Exelixis. “His broad and successful legal experience, particularly with regard to pharmaceutical marketing and commercialization, makes him well prepared to guide us through the complex issues that arise as we continue our transformation into a global commercial organization.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,472.37 +200.36 1.23%
S&P 500 1,951.36 +27.54 1.43%
NASDAQ 4,707.7750 +80.6910 1.74%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs